Nerviano Medical Sciences - Part of NMS Group

Dr. Frank Narjes Appointed as Head of Medicinal Chemistry and Drug Design, Elevating Innovation at Nerviano Medical Sciences Srl. NERVIANO, IT and BOSTON, Mass, May 13, 2024 - Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, welcomes Dr. Frank Narjes to the esteemed position of Head of Chemistry, heralding a new chapter of pioneering scientific exploration and innovation. With an illustrious career marked by transformational achievements and a relentless pursuit of excellence, Frank brings a wealth of expertise to lead NMS’ chemistry division into unprecedented realms of discovery. Dr. Frank Narjes' appointment underscores his exceptional leadership abilities and contributions to the field of chemistry. With a proven track record as a strong team leader, Dr. Frank has cultivated, trained, and empowered cross-functional teams, delivering clinical candidates and driving success in pre-clinical project endeavors. His extensive experience spans a diverse array of projects, including small molecule, peptide, antibody, and PROTAC initiatives, demonstrating a versatile skill set that aligns seamlessly with NMS’ multidisciplinary approach to research. Notably, Dr. Narjes' contributions have been recognized on a global scale, with invitations to speak at medicinal chemistry conferences and a prolific publication record comprising over 60 research articles and co-inventorship of 40 patents. Throughout his career, Dr. Narjes has demonstrated a remarkable ability to devise scientific strategies, navigate complex challenges, and engage stakeholders at every level. His tenure at AstraZeneca, where he served in various leadership roles in Medicinal Chemistry, including Senior Principal Scientist and Project Leader, underscores his unwavering commitment to advancing scientific knowledge and driving tangible outcomes. His strategic oversight has been instrumental in overseeing chemistry outsourcing, leading pre-clinical project teams, and steering the introduction of innovative modalities such as peptides and targeted protein degraders into the company’s portfolio. "We are thrilled to welcome Frank as the new Head of Chemistry at NMS," said Hugues Dolgos, Pharm.D., Chief Executive Officer and ad interim Chief Scientific Officer. "His proven leadership, strategic vision, and unparalleled dedication to scientific excellence make him the ideal candidate to lead our chemistry division into a future defined by innovation and discovery." Link PR: https://lnkd.in/dCcykgPU

NMS Srl is pleased to announce the participation of Lisa Mahnke, MD, PhD, Chief Medical Officer of NMS Srl and CEO/Managing Director of NMS-US, as a Discussant in the upcoming round table discussion "(BIO)TECH: The Future of Biomedical Research." The event is organized by Professionisti Italiani a Boston and will convene approximately 80 C-level executives from small biotech firms, VPs from pharmaceutical companies, and around 20 partners from venture capital and investment funds. When: May 7, 2024 @ 6:00 pm – 8:00 pm (EDT) Location: Federal Reserve Building, 600 Atlantic Ave, Boston, 4th fl.   Online Webinar registration page: https://lnkd.in/dpcwsVgt Nerviano Medical Sciences - Part of NMS Group has long been focusing on discovery and clinical development of small molecule NCEs for oncology from Nerviano (Milan), Italy with a legacy for more than half a century. Our fully owned subsidiary, NMS-US has been set up in Boston since 2022 and Lisa is on the driving seat to lead the collaboration both with local and global partners to accelerate our clinical development with our oncology forward approach. Her participation to the round table discussion of this key event organized by Professionisti Italiani a Boston reflects our heritage and future direction, and we are proud to contribute to projecting and shaping the growth of the biotech industries in both areas. #biotech #oncology #future #development #collaboration #event #tech

Nerviano Medical Sciences S.r.l. is presenting at the SWISS BIOTECH DAY 2024 in Basel!   We are presenting at the SWISS BIOTECH DAY 2024 partnering event in Basel, 22 April, 17.30-17.45 CEST Antonella Isacchi, Head of External Innovation Portfolio, Nerviano Medical Sciences - Part of NMS Group will present the Company and Nerviano Bio-Park at the #SwissBiotechDay on 22 April at 17.30 CEST. We look forward to seeing you there and don’t forget to come and visit the NMS Group Companies at the Delegation of Italy booth in the Global Village to discuss potential collaborations and partnering opportunities!   #swissbiotechday Swiss Biotech Association https://lnkd.in/dnqmCuSk

Nerviano Medical Sciences S.r.l. will attend the SWISS BIOTECH DAY 2024 partnering event in Basel, Switzerland Nerviano Medical Sciences - Part of NMS Group and the NMS Group affiliates Accelera - Part of NMS Group and NerPharMa - Part of NMS Group, will participate to the #SWISS_BIOTECH_DAY_2024 partnering event, which will be held in the Congress Center Basel, Switzerland on April 22-23, 2024. Come to visit us at the Delegation of Italy booth in the Global Village to discuss potential collaborations and partnering opportunities. See you in Basel! Swiss Biotech Association #swissbiotechday #NMS #Accelera #NerPharMa Link: https://lnkd.in/d8r-FgXJ

Nerviano Medical Sciences S.r.l. will attend the SWISS BIOTECH DAY 2024 partnering event in Basel, Switzerland Nerviano Medical Sciences - Part of NMS Group and the NMS Group affiliates Accelera - Part of NMS Group and NerPharMa - Part of NMS Group, will participate to the #SWISS_BIOTECH_DAY_2024 partnering event, which will be held in the Congress Center Basel, Switzerland on April 22-23, 2024. Come to visit us at the Delegation of Italy booth in the Global Village to discuss potential collaborations and partnering opportunities. See you in Basel! Swiss Biotech Association #swissbiotechday #NMS #Accelera #NerPharMa Link: https://lnkd.in/d8r-FgXJ

Nerviano Medical Sciences - Part of NMS Group to present data on MPS1 inhibitor NMS-153 and on ADC platform at the AACR annual meeting 2024 in San Diego, from April 5 to April 10.   Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the American Association of Cancer Research annual meeting that will be held in San Diego (AACR 2024) from April 5th to April 10th, 2024, with two poster presentations:   “The MPS1/TTK inhibitor, NMS-01940153, synergizes with tisotumab vedotin in colorectal cancer”, presented by Dr. Claudia Perrera on April 7th, session 21, 1:30 pm -5:00 pm (PDT) “A novel platform of diversified cytotoxins and targeted payloads to drive ADC innovation”, presented by Dr. Barbara Valsasina on April 9th, session 22, 1:30 pm -5:00 pm (PDT)   Links to posters will be available after the sessions. We look forward to welcoming you in San Diego!

Nerviano Medical Sciences - Part of NMS Group to present data on MPS1 inhibitor NMS-153 and on ADC platform at the AACR annual meeting 2024 in San Diego, from April 5 to April 10.   Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the American Association of Cancer Research annual meeting that will be held in San Diego (AACR 2024) from April 5th to April 10th, 2024, with two poster presentations:   “The MPS1/TTK inhibitor, NMS-01940153, synergizes with tisotumab vedotin in colorectal cancer”, presented by Dr. Claudia Perrera on April 7th, session 21, 1:30 pm -5:00 pm (PDT) “A novel platform of diversified cytotoxins and targeted payloads to drive ADC innovation”, presented by Dr. Barbara Valsasina on April 9th, session 22, 1:30 pm -5:00 pm (PDT)   Links to posters will be available after the sessions. We look forward to welcoming you in San Diego!

Nerviano Medical Sciences establishes its Scientific Advisory Board Nerviano, IT and Boston, Mass, 26 March, 2024 - Nerviano Medical Sciences S.r.l. (NMS), and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS S.r.l., focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced the formation of their Scientific Advisory Board (SAB), with the appointments of David Barbie, MD and David Feltquate MD, PhD, two accomplished scientific and medical leaders in Oncology with significant expertise in immunotherapy, clinical development, and translational medicine. The SAB met today to review key aspects of the NMS clinical portfolio and are looking forward to additional scientific and clinical discussions. “We are proud to welcome our SAB members. These outstanding experts will provide scientific guidance and critical insight to ensure NMS novel therapeutics might make a meaningful impact on the lives of patients worldwide. I am highly honored that NMS will be guided by David Barbie and David Feltquate and look forward to working closely with them.” said Lisa Mahnke, MD, PhD, CMO of NMS, CEO and Managing Director of NMS-US. Read more: https://lnkd.in/ddHaSfFn

Nerviano Medical Sciences establishes its Scientific Advisory Board Nerviano, IT and Boston, Mass, 26 March, 2024 - Nerviano Medical Sciences S.r.l. (NMS), and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS S.r.l., focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced the formation of their Scientific Advisory Board (SAB), with the appointments of David Barbie, MD and David Feltquate MD, PhD, two accomplished scientific and medical leaders in Oncology with significant expertise in immunotherapy, clinical development, and translational medicine. The SAB met today to review key aspects of the NMS clinical portfolio and are looking forward to additional scientific and clinical discussions. “We are proud to welcome our SAB members. These outstanding experts will provide scientific guidance and critical insight to ensure NMS novel therapeutics might make a meaningful impact on the lives of patients worldwide. I am highly honored that NMS will be guided by David Barbie and David Feltquate and look forward to working closely with them.” said Lisa Mahnke, MD, PhD, CMO of NMS, CEO and Managing Director of NMS-US. Read more: https://lnkd.in/ddHaSfFn

Nerviano Medical Sciences S.r.l. to present data on its platform of payload linkers for ADC conjugation at the World ADC Summit 2024 in London, UK (March 12th-15th, 2024) Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2024 summit that will be held in London, UK (World ADC Europe) from March 12th to March 15th, 2024, with a poster presentation entitled: “A payload-linker generating machine to quickly move from small molecules to characterized tool ADCs and PDCs” NMS, leveraging on its proprietary chemical collection and applying a rigorous screening funnel, generated a portfolio of characterized payload linkers with diversified MoAs to target different tumor types. Pillars of available technology are: 1) NMS-P945, a ‘plug-and-play’ thienoduocarmycin, active in chemoresistant cells, showing bystander effect and immunogenic cell death properties, highly efficacious in vivo in preclinical models and greater nonclinical safety profile, 2) next generation anthracycline payload linkers with improved stability and safety profile, both DNA damaging agents, 3) novel payloads. NMS seek for collaborations with partners having an established expertise in biologics to launch new innovative projects. #WorldADC2024 #Biotech #InnovativeTherapies #ADCConjugation #PayloadLinkers